Baxter International, Inc. is separating its global healthcare company into two separate businesses focused on biopharmaceuticals and medical products. Both businesses will be independent companies. The biopharmaceuticals business will focus on developing its pipeline of therapies through in-licensing collaborations, and the company has recently expanded its medical products portfolio with the acquisition of Gambro AB, a global provider of dialysis products.   Baxter aims to benefit from the sta...